Lung Cancer


 Stage IB, II, IIIA

  • Alliance A081105Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
  • Alliance A151216– Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
  • ECOG E4512– Randomized Phase III Double-Blind Trial for Surgical Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein


  • NRG LU001– A Randomized Phase II Trail of Concurrent Chemoradiotherapy +/- Metformin HL in Locally Advanced NSCLC
  • RTOG 1306– A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III NSCLC


  • SWOG S1400A Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Stage IIIB/IV  Lung Cancer (S1400E, S1400C is permanently closed)


  • CALGB 30610– Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited SCLC also Receiving Cisplatin and Etoposide
  • NRG-CC003– A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

Metastatic Lung Cancer

  •  RTOG 0631– A Randomized Phase II/III Study of Image Guided Radiosurgery/SBRT for Localized Spine Metastasis
  • SWOG 1403– A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer